Dr. Alain Pralong obtained his doctorate in molecular and cellular biology in apoptosis research at the University of Berne in 2000. Until 2004, he worked at Schering-Plough on Adenoviruses for a gene therapy clinical trial. Following a move to Roche, he managed the transfer of the Avastin manufacturing process from Genentech. From 2007 to 2008, he led at Merck-Serono the commercial manufacturing of human hormones.
Dr. Pralong served as Vice President at Crucell leading the Global Process Development Department working on mAbs and vaccines until the acquisition of Crucell by J&J in 2011. At GSK 2011, Alain served as Vice President New Product Introduction & Technical Life Cycle Management. From 2015 to 2018, Alain was SVP Manufacturing Operations for Cell Medica.
In 2018, Dr. Pralong has worked for AMAL Therapeutics before joining AgenTus Therapeutics where he worked as VP for Process Development, Manufacturing and Quality Assurance in Belgium and the US. Since 2020, Dr. Pralong is working as CEO of Pharma-Consulting ENABLE GmbH assisting various clients in the Cell & Gene Therapy, mAb and Vaccines field. Dr. Pralong has been listed in the 100 most influential people in biopharmaceutical industry issued by The Medicine Maker in 2015 and works as Associate Professor at the Polytech of the University Aix-Marseille.